Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial

– First patient dosed in trial to evaluate the safety, pharmacokinetics and pharmacodynamics of TOUR006 in patients with inflammatory risk and chronic kidney disease –

– Topline data anticipated in the first half of 2025 with potential to advance TOUR006 toward Phase 3 readiness for atherosclerotic cardiovascular disease (ASCVD) and other cardiovascular diseases –

– TRANQUILITY trial intended to provide evidence of TOUR006’s best-in-class potential for ASCVD, including the potential for quarterly subcutaneous dosing –

NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that the first patient has been dosed in its Phase 2 TRANQUILITY trial, marking the initiation of its clinical development program for TOUR006, a long-acting, fully human, anti-IL-6 monoclonal antibody, for the treatment of atherosclerotic cardiovascular disease (ASCVD) and other cardiovascular diseases. TRANQUILITY is a randomized, double-blind, placebo-controlled trial enrolling patients with inflammatory risk, manifesting as elevated high-sensitivity C-reactive protein (hs-CRP) at baseline, and chronic kidney disease (CKD).

“New treatments are sorely needed for the millions of patients who remain at very high risk of heart attack, stroke, acute limb ischemia, and death despite traditional risk factor modification,” said Emil deGoma, MD, Senior Vice President of Medical Research at Tourmaline and former Medical Director of the Preventive Cardiovascular Program at the University of Pennsylvania. “Converging evidence from IL-6 human genetic studies, epidemiological studies, and mechanistic experiments as well as analyses from clinical trials of upstream IL-6 inhibition supports the therapeutic potential of IL-6 inhibition for patients across the spectrum of ASCVD as well as for patients with other cardiovascular diseases, including heart failure.”

The design of the TRANQUILITY clinical trial was informed by insights from six prior Phase 1 and Phase 2 studies of TOUR006. If successful, results from the Phase 2 TRANQUILITY trial are expected to position Tourmaline to be Phase 3-ready in 2025 for ASCVD and other cardiovascular diseases.

“TOUR006 is a true ‘pipelines in a product’ opportunity, seeking to address both serious cardiovascular diseases for which IL-6-driven inflammation plays a key role as well as serious autoimmune disorders, such as thyroid eye disease,” continued Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline. “We believe TRANQUILITY can showcase TOUR006’s potential as a best-in-class treatment in these indications, offering ease of use and enabling consistent patient adherence, thanks to a potential quarterly dosing schedule. We look forward to sharing topline results from TRANQUILITY in the first half of 2025.”